ANGLE has completed a placing of new ordinary shares
ANGLE Plc has raised funds to develop the company.
ANGLE, through its subsidiaries, engages in providing products in cancer diagnostics and foetal health. Its main product is the Parsortix cell separation system, which can capture very rare cells from the blood. The company was founded by Andrew D. W. Newland in April 1994 and is headquartered in Guildford, UK.
Oaklins Cavendish’s sister firm finnCap, based in the UK, in its role as nominated advisor and joint broker, assisted ANGLE’s management team and shareholders all the way, from the start to the successful completion of the placing. During this process, the team initiated and advised on many aspects, including, among others, securing pre-commitments from cornerstone investors, seeking new institutional investors, deal structuring, document drafting, liaising with the exchange and the placing pricing and sizing.


Talk to the deal team
Related deals
Banco BPM Vita S.p.A. has launched a voluntary public tender offer for Anima Holding S.p.A.
Banco BPM Vita S.p.A. has initiated a voluntary public tender offer for the shares of Anima Holding S.p.A.
Learn moreTerra Holding S.r.l. has launched a voluntary public tender offer for Gibus S.p.A.
Terra Holding S.r.l. has initiated a voluntary public tender offer for the shares of Gibus S.p.A.
Learn morePharma-Skan & Skan-Medic have been acquired by Brygge Partners
Pharma-Skan, an independent contract manufacturing organization (CMO), and Skan-Medic, a manufacturer of over-the-counter (OTC) products, both operating as a joint entity, have been acquired by Brygge Partners.
Learn more